ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Cardiovascular Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

15,620Medicare Part D Prescriptions Filled, Including Refills

Rank: 2 out of 130

$529K Total Retail Price of All Prescriptions

Rank: 5 out of 130

1,311 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
26% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Iowa
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

0% of this provider’s 13,744 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

15% of this provider’s prescriptions were for brand-name drugs, compared to an average of 19%.

Prescription Price

$34 was the average price of a prescription from this provider, compared to $44 among peers.

Prescriptions per Patient

12 is the average number of prescriptions (including refills) per patient, compared to an average of 10.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Iowa
LISINOPRIL 1,261 971 1 4
SIMVASTATIN 1,242 1,128 2 2
CARVEDILOL 1,197 1,057 3 6
PRAVASTATIN SODIUM 771 693 4 18
FUROSEMIDE 723 665 5 5
AMLODIPINE BESYLATE 669 619 6 7
ATORVASTATIN CALCIUM 546 470 7 9
LOSARTAN POTASSIUM 523 487 8 14
SPIRONOLACTONE 428 366 9 17
BISOPROLOL-HYDROCHLOROTHIAZIDE 377 330 10 59
METOPROLOL TARTRATE 369 319 11 1
WARFARIN SODIUM 346 339 12 8
LISINOPRIL-HYDROCHLOROTHIAZIDE 317 298 13 35
POTASSIUM CHLORIDE 289 271 14 16
METOPROLOL SUCCINATE 279 216 15 3
BISOPROLOL FUMARATE 278 239 16 25
HYDROCHLOROTHIAZIDE 266 230 17 20
LOSARTAN-HYDROCHLOROTHIAZIDE 250 230 18 37
CRESTOR 206 171 19 19
FENOFIBRATE 205 192 20 33
SOTALOL 204 185 21 21
ISOSORBIDE MONONITRATE ER 195 165 22 10
BENAZEPRIL HCL 189 185 23 32
CLOPIDOGREL 188 155 24 11
DILTIAZEM 24HR CD 171 146 25 24
HYDRALAZINE HCL 166 138 26 42
TAMSULOSIN HCL 162 160 27 77
NITROSTAT 156 132 28 23
DOXAZOSIN MESYLATE 154 142 29 50
PLAVIX 125 100 30 13
AMIODARONE HCL 117 117 31 22
AMLODIPINE BESYLATE-BENAZEPRIL 114 102 32 61
ATENOLOL 112 94 33 12
DILTIAZEM ER 111 82 34 31
GEMFIBROZIL 109 99 35 56
CLONIDINE HCL 102 71 36 43
ZETIA 95 74 37 26
PRADAXA 91 84 38 29
ENALAPRIL MALEATE 87 75 39 27
RAMIPRIL 87 67 39 28
BUMETANIDE 84 67 41 54
NADOLOL 83 83 42 90
NIFEDIPINE ER 79 75 43 47
DIGOXIN 77 68 44 15
LIPITOR 68 50 45 52
TERAZOSIN HCL 67 67 46 75
ALLOPURINOL 62 61 47 62
DILTIAZEM HCL 62 59 47 71
VERAPAMIL ER 61 49 49 51
CILOSTAZOL 58 58 50 69
LOVASTATIN 56 52 51 65
PROPAFENONE HCL 55 54 52 38
TRIAMTERENE-HCTZ 54 54 53 46
BYSTOLIC 52 42 54 36
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 8, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.